Article
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
Genes & development - 1 Sept 2012
Andreadi Catherine, Cheung Lai-Kay, Giblett Susan, Patel Bipin, Jin Hong, Mercer Kathryn, Kamata Tamihiro, Lee Pearl, Williams Alexander, McMahon Martin, Marais Richard, Pritchard Catrin
Abstract excerpt
(L597V)BRAF mutations are acquired somatically in human cancer samples and are frequently coincident with RAS mutations. Germline (L597V)BRAF mutations are also found in several autosomal dominant developmental conditions known as RASopathies, raising the important question of how the same mutation can contribute to both pathologies. Using a conditional knock-in mouse model, we show that endogenous expression of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.